<bill session="117" type="h" number="7346" updated="2022-12-29T22:18:23Z">
  <state datetime="2022-03-31">REFERRED</state>
  <status>
    <introduced datetime="2022-03-31"/>
  </status>
  <introduced datetime="2022-03-31"/>
  <titles>
    <title type="display">John W. Walsh Alpha-1 Home Infusion Act of 2022</title>
    <title type="short" as="introduced">John W. Walsh Alpha-1 Home Infusion Act of 2022</title>
    <title type="official" as="introduced">To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="S000168"/>
  <cosponsors>
    <cosponsor bioguide_id="C001078" joined="2022-05-27"/>
    <cosponsor bioguide_id="H001038" joined="2022-04-21"/>
    <cosponsor bioguide_id="J000020" joined="2022-09-20"/>
    <cosponsor bioguide_id="J000306" joined="2022-09-21"/>
    <cosponsor bioguide_id="K000375" joined="2022-10-25"/>
    <cosponsor bioguide_id="L000557" joined="2022-11-29"/>
    <cosponsor bioguide_id="O000086" joined="2022-09-30"/>
    <cosponsor bioguide_id="P000613" joined="2022-09-28"/>
    <cosponsor bioguide_id="P000597" joined="2022-03-31"/>
    <cosponsor bioguide_id="P000599" joined="2022-09-13"/>
    <cosponsor bioguide_id="R000305" joined="2022-10-25"/>
    <cosponsor bioguide_id="T000460" joined="2022-10-04"/>
    <cosponsor bioguide_id="T000469" joined="2022-05-03"/>
    <cosponsor bioguide_id="W000797" joined="2022-04-21"/>
    <cosponsor bioguide_id="Y000062" joined="2022-11-10"/>
  </cosponsors>
  <actions>
    <action datetime="2022-03-31">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-03-31" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2022-03-31">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2022-04-01">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-06-17T13:37:00Z" status="Introduced in House">John W. Walsh Alpha-1 Home Infusion Act of 2022

This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.</summary>
</bill>
